Clinical aspects in neurosarcoidosis anterior visual pathway

• Research type

  Research Study

• Full title

  The manifestations and efficacy of current therapies for neurosarcoidosis with anterior visual pathway involvement

• IRAS ID

  328881

• Contact name

  Tarunya Arun

• Contact email

  tarunya.arun@uhcw.nhs.uk

• Sponsor organisation

  University Hospitals of Coventry and Warwickshire

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  1 years, 0 months, 1 days

• Research summary

  Sarcoidosis is an inflammatory disease that affects multiple organs in the body. In people with sarcoidosis, abnormal masses or nodules (called granulomas) consisting of inflamed tissues form in certain organs of the body. These granulomas may alter the normal structure and possibly the function of the affected organ(s). Sarcoidosis most often occurs between 20 and 40 years of age. It is estimated that up to one in 10,000 people in the UK have sarcoidosis. It can present in a variety of ways, ranging from a mild, acute self-limiting disease to chronic disease involving several organs and causing severe symptoms and functional impairment. Overall mortality in sarcoidosis is 1-5%, usually due to pulmonary, cardiac or neurological involvement or their complications (Sarcoidosis UK, 2018).

  Neurosarcoidosis refers to a type of sarcoidosis affecting the nervous system which includes the brain, spinal cord, or peripheral nerves. Neurosarcoidosis occurs in approximately 5-10% of people with sarcoidosis. About 100 people are diagnosed with neurosarcoidosis in the UK each year (NICE Evidence Review, 2018). It can affect the central nervous system (CNS, the brain and spinal cord) and peripheral nervous system (including the 12 cranial nerves supplying the head and neck). Neurosarcoidosis has no known cure and whilst spontaneous remission has been observed, early identification and long-term treatment is often required to prevent severe disability and even death.
  Identification of neurosarcoidosis constitutes one of the most crucial aspects of sarcoidosis as delays in diagnosis may lead to an unfavorable prognostic outcome for the patient, including severe disability and death. Timely identification and treatment are key and we will study the visual pathway manifesatations of neurosarcoidosis that will distinguish this from its common mimic multiple sclerosis

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  23/EE/0231

• Date of REC Opinion

  11 Oct 2023

• REC opinion

  Further Information Favourable Opinion